A crypto user lost approximately $50 million in a token swap transaction on Thursday. On-chain data shows that the user exchanged about $50.43 million worth of aEthUSDT for aEthAAVE through the CoW Protocol, but due to insufficient liquidity pool depth, the transaction experienced a slippage of over 99%, ultimately resulting in the user receiving only about 327 aEthAAVE, worth approximately $36,000, with the difference being captured by arbitrage traders and network intermediaries.
Aave founder Stani Kulechov posted on the X platform that the user purchased AAVE using $50 million USDT through the Aave interface. Due to the unusually large size of the single order, the interface issued an extreme slippage warning to the user and required confirmation. After accepting the warning on a mobile device, the user proceeded with the transaction.
Kulechov stated that the CoW Swap router operated as expected and followed industry-standard operating procedures, but the outcome was clearly not ideal. Kulechov mentioned that Aave plans to contact the user and refund approximately $600,000 in fees charged from the transaction. Days before this incident, about $27 million in positions on Aave were liquidated, and some market participants believe that this liquidation may be related to a temporary pricing issue with wstETH.
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.





Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.















Long-end U.S. Treasury yields surged to multi-year highs, pressuring technology, semiconductor, storage, and optical communication stocks and driving a clear cooling in market risk appetite. At the same time, Anthropic’s revenue came in below some bullish expectations, prompting investors to reassess the AI growth narrative; Unitree Robotics officially listed on the STAR Market, extending momentum in robotics and embodied AI; while SpaceX and other commercial space names showed relative resilience. Investors are now focused on tonight’s Federal Reserve minutes for clearer signals on the policy path and broader market sentiment.










Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.